TEM stock news · Tempus AI, Inc.
Get alerts for TEM
Follow Tempus AI, Inc. (TEM) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TEMTempus AI, Inc.: Other Events (TEM)
Good for TEMTempus signed data and software agreements with Bristol Myers Squibb and Pathos worth $192.5 million over about 5 years. The payments support a positive read, though some depend on record delivery.
Cathie Wood responds to critics, saying comparing ARKK's 15% drop to QQQ's 112% rise isn't fair.
NeutralTempus AI is named among ARKK's healthcare and biotech holdings, but the story gives no new company result or change. It does not change Tempus AI's outlook.
A new analyst starts following Digital Realty Trust with a positive outlook and shares the top 5 picks for Monday.
Bad for TEMTempus AI was started with a Neutral rating and a $75 price target, which is below the $77.84 close and implies limited upside from the analyst view.
Tempus AI shares rise on Friday: Factors behind the surge.
Good for TEMTempus AI's stock is climbing following the positive Phase 3 results from Merck and Moderna, which are linked to its recent acquisition of Personalis. This acquisition strengthens Tempus's position in the personalized medicine space, particularly in cancer treatment, and is driving investor interest.
Tempus AI shares rise on Thursday amid sustained Buy rating and major Personalis acquisition.
NeutralTempus AI's stock is experiencing gains following a maintained Buy rating and a significant acquisition of Personalis, which is linked to a successful cancer trial involving Merck and Moderna. This connection enhances the potential for Tempus AI's growth in the healthcare sector.
Tempus AI's stock surges after Merck and Moderna's cancer trial confirms the value of its Personalis acquisition.
Good for TEMTempus AI's shares are experiencing a significant rally following the announcement of positive Phase 3 trial results from Merck and Moderna, which validate Tempus's recent acquisition of Personalis. This connection enhances Tempus's position in the personalized medicine space, driving investor confidence and stock performance.
Tempus AI shares experience a notable rise on Friday.
Good for TEMTempus AI's stock is experiencing a significant surge, primarily driven by a broader rally in the AI-healthcare technology sector following strong earnings from Doximity. This momentum is further supported by Tempus's recent collaboration with CellCarta, enhancing its market position in oncology diagnostics.